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Which type of fluid to use perioperatively?
Fluid management is a fundamental part of the daily 
clinical practice of anesthesiologists and intensivists. 
Careful consideration should be given to fluid management 
with amongst others evaluation of type of fluid, dosing, 
administration strategy, and potential side-effects. 
This review focuses on these important aspects of fluid 
management in perioperative care. First, a short history will 
be presented and basic physiology and indications for fluid 
therapy will be discussed. Second, different types of fluid 
will be discussed, with the exception of blood products. 
Third, different types of strategies to help guide fluid 
management will be addressed.
Physiology
History
The British physician Will iam B. O’Shaughnessy 
(1809–1889) was the first to describe that cholera 
patients lost a lot of water and electrolytes (“neutral 
saline ingredients”) from their blood, and he suggested 
to administer fluids intravenously to restore the normal 
composition of blood (1). His idea was put to clinical 
practice by Dr. Thomas A. Latta (1796–1833) who was 
the first to administer intravenous fluids to a patient (2). 
During the cholera epidemic in London in 1831, Latta 
tried to replace the lost fluids and salts from one of his 
patients by injecting fluids into the larger intestine of the 
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patient and letting the patient drink from time to time. 
Unfortunately, this act did not appear to result in any 
benefit for the patient. So, Latta decided to administer the 
(unsterile!) fluids directly into the circulation of the patient. 
The patient was given several boluses of a fluid, which 
was similar to what we now would call ½ Ringer’s lactate, 
via the basilic vein. During the fluid administration the 
breathing of the patient immediately became less labored, 
the pulse became stronger and less frequent, and the patient 
improved clinically. The woman exclaimed afterwards that 
she was ‘free from all uneasiness’ and Latta declared her 
cured (2-5). 
In the 19th century the British clinician, physiologist and 
pharmacologist Sidney Ringer (1835–1910) developed a 
solution as a fluid replacement for blood loss (6), and late 
in the 19th century the first sterile fluids were developed 
(7). In the early 1900’s a 0.9% NaCl solution (also known 
as “normal” or physiological saline) was developed by 
Hartog J. Hamburger (1859–1924), a physiological chemist 
(7). All of these fluids were classified as crystalloids, i.e., 
solutions containing small molecules (electrolyte salts or 
glucose) dissolved in water. In 1913 a 0.9% NaCl solution 
was combined with ‘the purest gelatin’, a colloid, and this 
solution was administered for the first time to a trauma 
patient with a successful outcome (8). The theoretical 
reason for adding colloids to the replacement fluids was that 
these larger molecules were thought to stay longer within 
the vasculature and did not vanish into the extravascular 
space as easily as water and electrolytes. 
Developments in fluids were ongoing and in 1932 a 
lactate buffer was added to Ringer’s solution by Alexis F. 
Hartmann, pediatrician and chemical pathologist, and 
Milton J.E. Senn, pediatric psychiatrist (9). They added 
this buffer to the solution in order to make the composition 
more similar to that of blood and reduce the amount of 
chloride, since it became apparent that chloride caused 
acidosis (10). It took up until the second world war before 
colloids were frequently used to replace blood losses. 
Albumin solutions became frequently used replacement 
fluids for soldiers with trauma on the battlefield (11). 
Over the past 200 years the general concept of 
resuscitating with fluids has stayed the same. Nowadays 
a differentiation is made between maintenance and 
replacement fluid therapy. The latter should be given 
preferably guided by hemodynamic variables, i.e., goal-
directed. 
Physiology
The goals of perioperative fluid management are to 
optimize fluid balance, optimize plasma constitution, secure 
sufficient circulation of blood and thus sufficient oxygen 
delivery to organs in order to prevent organ dysfunction 
(12,13). Throughout the perioperative period a broad range 
of events can lead to insufficient oxygen being delivered 
to the organs. Overall, the indications to give fluids can be 
divided into two categories; maintenance and replacement 
therapy. Maintenance therapy is given to compensate for 
fasting, i.e., absence of the normal fluid intake. Replacement 
therapy is needed when hemorrhagic or non-hemorrhagic 
causes (e.g., fluid shifts or vasodilation) result in absolute or 
relative volume depletion (14). When resuscitation fluid is 
administered a cascade of reactions takes place, which will 
eventually prevent deterioration of organ function. Yet, at 
every step physiological or pathological mechanisms can 
obstruct or prevent this process from happening. Figure 1 
shows a schematic representation of this process.
The first step in the cascade begins immediately 
after the administration of fluids with an increase in 
intravascular volume. However, capillary leakage can 
prevent administration of a fluid bolus form increasing 
intravascular volume (15). The glycocalyx is a layer 
consisting of proteoglycans on the vascular endothelium 
that contributes to the barrier function of the endothelium, 
which plays a very important role in vascular permeability 
(16). Ischemia and reperfusion, hypoxia, hypervolemia, 
sepsis, inflammatory activation and hyperglycemia can all 
cause a loss of integrity of the glycocalyx (17). 
When there is no or minimal capillary leakage the 
intravascular volume increases after fluid administration. 
The intravascular volume can be separated in stressed and 
unstressed vascular volume. Unstressed vascular volume 
is the volume needed to fill the vessels without putting 
pressure on the vascular wall. The stressed blood volume is 
the volume which stretches the vascular wall and determines 
the mean systemic filling pressure (18). When vasodilatation 
occurs the unstressed part of the vascular volume increases 
and less volume remains to stretch the vascular wall, which 
will lead to a decreased mean systemic filling pressure (13). 
An increase in mean systemic filling pressure, the driving 
force behind venous return and thus right ventricular 
preload, can lead to an increase in cardiac output (CO) if 
the heart acts on the steep part of the Frank-Starling curve 
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and can cope with the increased preload. The patient is in a 
preload responsive state which is also called fluid responsive. 
However, if the heart acts on the horizontal part of the 
Frank-Starling curve or is failing, CO will not increase 
following a fluid bolus and the patient is in a preload 
unresponsive state (19,20). Figure 2 shows a visualization 
of the Frank-Starling curve for both a normal and a failing 
ventricle.
An increase in CO has a direct and an indirect effect 
on the microcirculation. First, an increase in CO directly 
increases flow through these small vessels, and second CO 
increases mean arterial pressure, which increases the amount 
of perfused vessels (21), when there is no microcirculatory 
impairment. An increased proportion of perfused vessels 
and increased flow will result in an increased amount of 
oxygen delivery to the organs (DO2). Yet, this effect might 
be attenuated by hemodilution caused by the infused fluids 
(22). As a result of an increased DO2 organ function should 
be prevented from deterioration, unless hypoxia has been 
ongoing and has caused structural and irreversible damage 
to the organ tissue.
Types of fluid
Crystalloids
Crystalloid solutions contain minerals or other water-
soluble molecules dissolved in water. Frequently used 
crystalloids are 0.9% NaCl, Ringer’s lactate or glucose 
5% (Table 1). Crystalloids and colloids can be balanced or 
unbalanced. In balanced fluids chloride is partially replaced 
by other anions. Also, potassium is added to make these 
solutions more equal to the composition of blood (23). 
Several studies have assessed the effects of balanced versus 
unbalanced crystalloid solutions. Unbalanced fluids, 
especially 0.9% NaCl, can cause hyperchloremia (24) 
and can lead to hyperchloremic metabolic acidosis (25,26). 
Hyperchloremia has been associated with increased risk 
of mortality (OR 2.05; 95% CI: 1.62–2.59) (27) and 
Figure 1 Schematic representation of the cascade that follows fluid 
administration (dark yellow boxes) and the processes that might 
interrupt the cascade of reactions (light yellow boxes).
Figure 2 The Frank-Starling curve shows when the heart of a 
patient is in a preload responsive or preload unresponsive state. 
The top line represents a normal functioning heart, the lower line 
represents a failing heart. Note that for the same preload, the heart 
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hyperchloremic acidosis potentially leads to adverse effects 
such as renal impairment (28) and immune dysfunction (29). 
These effects can be more pronounced in patients 
suffering from impaired renal function, due to difficulties 
in excreting chloride. 0.9% NaCl was also associated with 
postoperative infection, renal replacement therapy (RRT), 
blood transfusion and electrolyte imbalances compared 
to balanced crystalloid solutions, whereas balanced 
crystalloids had an overall tendency towards a reduced in-
hospital mortality (30,31). A study performed in healthy 
volunteers showed that a fluid bolus of two liters of 0.9% 
NaCl led to a decrease in renal blood flow and renal cortical 
perfusion compared to balanced crystalloid solutions (32). 
Another study showed in addition to these adverse effects 
that the amount of transfused blood volume was higher and 
mechanical ventilation times were longer in patients receiving 
0.9% NaCl compared to low-chloride containing fluids 
(24). Two recent trials, the SMART (33) and the SALT-ED 
(34) trial compared balanced crystalloids and 0.9% NaCl in 
critically ill and in noncritically ill patients. Both trials showed 
a lower incidence in major adverse kidney events (MAKE) at 
30 days when balanced crystalloids were used (OR 0.91; 95% 
CI: 0.84–0.99 and OR 0.76; 95% CI: 0.64–0.91 for SMART 
and SALT-ED, respectively). MAKE includes death from 
any cause, new RRT, or persistent renal dysfunction. Given 
the beneficial results, balanced crystalloids are preferred over 
0.9% NaCl, as they are more similar to the composition of 
human plasma (see Table 1) (35,36).
Colloids
Colloids are mainly used for replacement and not for 
maintenance of fluid balance. Colloids contain larger 
molecules than crystalloids such as gelatin, hydroxyethyl 
starch, dextran or albumin (23) (Table 1). These molecules 
do not dissolve in plasma so that colloids stay intravascularly 
longer than crystalloids. When the glycocalyx is intact, it is 
difficult for colloids to pass this barrier, while crystalloids 
can pass freely (37,38). In theory, most of the colloids 
administered will stay intravascular, whereas only 18% of 
administered balanced crystalloids will (39). Compared to 
crystalloids, the volume effect of colloids is also about 2–5 
times larger (40,41). In addition, there is a difference in 
colloid osmotic pressure between colloids and crystalloids. 
Crystalloids generally lower the colloid osmotic pressure 
and thus decrease the intravascular volume by inducing 
extravasation, whereas some colloids raise the colloid 
osmotic pressure and thus increase intravascular volume by 
causing fluid absorption from extravascular spaces.
Albumin is made using pooled fractionated blood from 
donors added to a crystalloid solution. This is a very time-
consuming and expensive process depending completely on 
human blood donors and thus semisynthetic colloids were 
developed. Albumin comes in different solutions: including 
a 4% hypo-oncotic, a 5% iso-oncotic and a 20% hyper-
oncotic solution, the latter with a fivefold higher volume 
effect (plasma expander). The SAFE trial randomized 7,000 











Human plasma 291 7.35–7.45 135–145 94–111 4.5–5.0
Crystalloids
0.9% NaCl 308 4.5–7.0 154 154 0
Ringer’s Lactate 273 6.0–7.5 130 109 4
Glucose 5% 278 3.5–5.5 0 0 0
Colloids
Albumin 5% 309 6.4–7.4 140 140 <2
6% HES 130/0.4 (Voluven) 308 4.0–5.5 154 154 0
Succinylated modified fluid gelatin (Gelofusine) 274 7.1–7.7 154 120 0
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ICU patients in need of fluid replacement to receive either 
albumin or saline and found no difference in survival at 
28 days (42). More recently, the ALBIOS trial reproduced 
this finding when albumin was compared to crystalloids in 
patients with sepsis (43).
Hydroxy-ethyl starch (HES) is an example of semi-
synthetic colloids (44). HES is derived from corn starch 
or potato starch, and has undergone several modifications 
(from hetastarch via pentastarch to tetrastarch) with an 
improved safety profile while maintaining its efficient 
volume effect. Modern HES containing products are also 
available as balanced solutions. HES products were widely 
used in the perioperative setting as well as in the ICU for 
volume replacement. However, several large randomized 
controlled trials (RCT) performed in critically ill patients 
with sepsis raised concerns about the safety of HES (45-47). 
These studies showed an increase in acute kidney injury 
(AKI), RRT, adverse events and mortality after the use of 
HES, as well as disturbances in coagulation (45-47). As 
a consequence of these large studies, the indication for 
HES was redefined. Furthermore, although all of these 
studies were performed in critically ill patients, the safety 
and efficacy of HES products has to be re-evaluated in the 
perioperative setting.
Gelatins are one of the oldest synthetic colloids (8). Since 
they were developed a long time ago, proper safety studies 
have never been conducted. Authors of a systematic review 
with meta-analysis performed in 2012 concluded that “despite 
over 60 years of clinical practice, the safety and efficacy 
of gelatin cannot be reliably assessed”, and the authors 
recommended to investigate and establish such safety (48).
An in vitro study showed that administration of different 
colloids led to an increase in clotting time and a decrease in 
clot firmness compared to administration of crystalloids (49). 
Possible reasons include the “coating” of platelets and 
hemodilution. 6% HES 130/0.4 showed higher reduction 
in fibrinogen and thrombin concentrations. Patients 
receiving HES compared to albumin and gelatin solutions 
had overall worse outcomes (50). A systematic review with 
meta-analysis assessed the difference in outcomes between 
crystalloids and colloids for critically ill, trauma and 
surgical patients and showed no increased risk for patients 
undergoing cardiac surgery which had received colloids. 
A sub-analysis of the group of patients which underwent 
general surgery also showed no increased risk of mortality 
in the HES group (51).
Since multiple studies showed adverse events after 
the use of HES, the European Medicines Agency (EMA) 
restricted the use of HES in 2013 and redefined the 
indication to hypovolemia due to blood loss, which meant 
that there no longer was an indication for HES products 
in critically ill patients. The EMA ordered the conduct of 
a drug utilization study which showed that HES was still 
sometimes given to critically ill patients which led them 
to consider to take HES from the market completely. An 
expert meeting recommended not to withdraw HES for 
several reasons: (I) withdrawing HES from the market might 
cause unmet medical needs, especially when replacement 
with crystalloids alone is insufficient, (II) the use of albumin 
will increase which is very costly and dependent on human 
plasma donors (52). The EMA decided to add further 
risk minimization measures to prevent the use of HES in 
patients at risk. An e-learning on the use of HES according 
to the European Product Information has been developed 
and is available online at the ESA Academy. Furthermore, 
on request of the EMA, the PHOENICS and TETHYS 
trials are currently being conducted and aim to look at 
safety and efficacy of use of HES in patients undergoing 
high-risk abdominal surgery (NCT03278548) and trauma 
patients (NCT03338218), respectively. 
Fluid management
Hypovolemic versus fluid overload
Both hypovolemia and hypervolemia are associated with 
postoperative complications, although it is very difficult 
to strictly maintain normovolemia as there is no clear 
definition of and no easy way to monitor normovolemia (53). 
Hypovolemia is associated with organ hypoperfusion, 
systemic inflammatory response syndrome, sepsis, multi-
organ failure and even mortality (53). Hypervolemia 
on the other hand is associated with tissue edema, 
ileus, postoperative nausea and vomiting, pulmonary 
complications and an increase in cardiac demand (53). A 
proof-of-concept study conducted in 48 surgical patients 
who were postoperatively admitted to the ICU showed that 
weight gain during surgery was associated with increased 
mortality. The group with less than 10% body weight gain 
(n=29) had a mortality rate of 10%, the group that gained 
10–20% body weight (n=16) had a mortality of 19%, and 
in the group that gained more than 20% body weight 
(n=3) all patients died (54). A study including patients 
undergoing cardiac surgery also showed that fluid overload 
was associated with mortality (OR 1.59; 95% CI: 1.18–2.14) 
(55).
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A large retrospective study of 90,000 patients undergoing 
non-cardiac surgery showed an association between 
perioperatively administered fluid volume and postoperative 
outcomes. The outcomes 30-day mortality, postoperative 
respiratory complications and AKI all showed a U-shaped 
curve pattern indicating that there might be an optimal 
level (sweet spot) of fluid administration. The same results 
were found for the outcomes length of hospital stay and 
total hospital cost (56).
Hypovolemia as well as fluid overload cause adverse 
postoperative outcomes. Several strategies for perioperative 
fluid management exist and numerous studies have shown 
that postoperative outcomes are influenced by perioperative 
fluid management strategies (57-60). Current strategies for 
fluid management include restrictive fluid therapy, liberal 
fluid therapy, and perioperative goal-directed therapy 
(PGDT).
Restrictive versus liberal fluid management
Since 1961 a liberal fluid strategy was promoted due to 
the observation that during major surgery a reduction 
in extracellular fluid occurred, presumably by internal 
fluid redistribution (61). In the following years no proper 
evaluation of liberal fluid management was performed and 
it took a few decades before the adverse outcomes of liberal 
fluid management were realized (62). More knowledge 
of the harmful effects of fluid overload caused several 
comparison studies to assess if a restrictive fluid strategy 
would be more beneficial for patient outcomes. One of the 
difficulties of comparing liberal and restrictive fluid therapy 
is the fact that these terms are not clearly defined, i.e., 
what is considered to be liberal fluid therapy in one study 
could be considered restrictive fluid therapy in another. A 
systematic review with meta-analysis assessed the difference 
in postoperative morbidity between a restrictive and a 
liberal fluid therapy approach and found a range of 998 
to 2,740 mL for a restrictive approach, whereas a liberal 
approach ranged from 2,750 to 5,388 mL (53). In this 
meta-analysis three studies showed a beneficial outcome 
when a restrictive approach was used in major abdominal 
surgery: length of stay, return of bowel function and overall 
decrease in complications (63-65). Two studies included 
in the meta-analysis showed no difference in outcome 
between a restrictive or a liberal approach (66,67). One 
study, conducted in orthopedic patients, showed improved 
pulmonary function and coagulation in the patient group 
receiving the liberal approach (68). Another study found 
improved pulmonary function, as well as improved post-
operative hypoxemia and reduced vasoactive hormonal 
response in the liberal approach, and the total number of 
complications was reduced with the liberal approach (69). 
Another systematic review with meta-analysis included 
twelve studies comparing liberal and restrictive fluid 
management (70). The included studies overlap with the 
abovementioned meta-analysis (53), however, an additional 
five studies were included and the primary outcome was 
mortality instead of postoperative morbidity (71-75). 
Pneumonia and pulmonary edema occurred more often 
in the group receiving liberal fluid therapy, as length of 
hospital stay and return of bowel function took longer in 
the liberal fluid management groups (70).
In the RELIEF trial, 3,000 patients undergoing 
abdominal surgery were included and allocated to a 
restrictive or a liberal fluid therapy (76). The restrictive 
group received a fluid bolus of 5 mL kg-1 during induction 
of anesthesia, after which the dose was reduced to 5 mL kg-1 
h-1 until the end of surgery and up until 24 h after surgery 
a dose of 0.8 mL kg-1 h-1 was given. For the liberal fluid 
strategy, the dosages were 10 mL kg-1 h-1, 8 mL kg-1 h-1 and 
1.5 mL kg-1 h-1, respectively. No difference was found for 
the primary outcome, which was disability free-survival one 
year after surgery. Furthermore, the incidence of AKI was 
slightly higher within the restrictive strategy, as well as RRT 
and surgical site infections.
In summary, restrictive and liberal fluid strategies are 
hard to compare since there are no clear definitions of 
how much fluid is administered in each of these strategies, 
leading to a lack of clear cut-off values separating both 
regimens. The optimal amount of volume needs to be 
administered at the right moments and only when a patient 
is in need of fluids, which can be detected by advanced 
hemodynamic monitoring. For this purpose, PGDT was 
developed, aiming at a more personalized approach.
Perioperative goal-directed therapy
The principle of PGDT is to assess fluid responsiveness and 
cardiac function using advanced hemodynamic monitoring 
in order to optimize oxygen delivery to the tissues (77). 
The obtained hemodynamic variables are used in an 
algorithm, which helps the anesthesiologist to make sure 
that the hemodynamic status of the patient is optimized. In 
these algorithms, fluid management is usually the primary 
intervention, which is however often combined with 
titration of vasopressors and inotropes. Figure 3 shows an 
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example of a PGDT algorithm. 
The introduction of the pulmonary artery catheter 
(PAC) in the 1980s led to the first trials using hemodynamic 
variables to guide perioperative therapy. Researchers 
noticed that survivors of trauma surgery often had 
‘supranormal’ values of hemodynamic values such as cardiac 
index (CI) and DO2 (78). An early systematic review with 
meta-analysis showed that obtaining these ‘supranormal’ 
hemodynamic values was only beneficial when started 
before the onset of organ failure and in patients with an 
expected mortality >20% (79). After decades of research and 
after development of less invasive hemodynamic monitors, 
dynamic hemodynamic variables such as stroke volume 
variation (SVV) and pulse pressure variations (PPV) were 
implemented in PGDT strategies as targets to help guiding 
fluid therapy.
Over the last couple of decades, a large number of studies 
have shown beneficial patient outcomes using PGDT. A 
recent systematic review with meta-analysis, including 95 
RCTs, showed that PGDT reduced mortality (OR 0.66; 
95% CI: 0.50–0.87). However, no mortality benefit was 
found in fluid-based-only algorithms, in cardiac surgery 
patients, or in non-elective surgeries. PGDT did also 
decrease the risk of AKI, pneumonia, wound infection and 
the hospital length of stay (80). Another systematic review 
with meta-analysis, including 37 RCTs, was conducted 
with the aim to assess the difference in PGDT using only 
fluids guided by dynamic variables versus standard (i.e., 
unmonitored) fluid therapy. The group where PGDT 
using only fluids was used showed a lower serum lactate 
than the standard fluid therapy group. Yet, no difference 
was found in short-term mortality, morbidity, and length of 
stay. When, however, the use of fluids was combined with 
additional optimization goals such as CO or CI, there was a 
reduction in short-term mortality, morbidity, serum lactate 
concentration, cardiopulmonary complications, heart 
failure/cardiovascular dysfunction, acute lung injury/acute 
respiratory distress syndrome, pneumonia, and length of 
stay in the ICU, and length of hospital stay (81).
Although there is a considerable evidence in favor of 
PGDT, it is still not commonly used in clinical practice. 
One of the reasons is heterogeneity in PGDT studies and 
all components of the PGDT algorithms (82). Therefore, 
the 5 ‘T’s’ have been suggested to help implement PGDT 
in clinical practice: target population, timing of the 
intervention, type of intervention, target variable, and 
target value (83). PGDT should be aimed at high-risk 
patients as target population. High risk patients can have 
patient specific features that increase risk of complications 
or are scheduled for a high-risk procedure. PGDT should 
be started early in the perioperative phase, preferably before 
anesthetic induction (80). The right choice of intervention 
should be made. This review aimed to focus solely on 
perioperative fluid use. Nonetheless, in order to provide 
best practice a complete PGDT algorithm should contain 
vasopressors and inotropes as well. The right variable 
should be targeted, preferably hemodynamic variables 
reflecting blood flow (81). Within the target variable the 
right target values must be pursued, and this goal might be 
quite difficult to achieve since the use of dynamic variables 
is limited to certain circumstances. Finally, blood pressure 
and CO targets should be individualized to patient specific 
baseline values (84). 
Currently two large RCTs are conducted to enrich the 
evidence on PGDT. In the first one, the Fluid Optimisation 
in Emergency LAparatomy trial (FLO-ELA), nearly 
8,000 patients will be included who are undergoing 
emergency bowel surgery in order to assess mortality when 
a cardiac-output guided hemodynamic therapy strategy is 
used (www.floela.org). In the second one, Optimisation of 
Peri-operaTive CardIovascular Management to Improve 
Surgical outcome II trial (OPTIMISE-II), 2,502 patients 
Figure 3 Example of a perioperative goal-directed fluid algorithm. 
†age-specific CI targets: <60 years =2.8 L min-1 m-2, 60–75 years 
=2.6 L min-1 m-2, >75 years =2.4 L min-1 m-2. SVV, stroke volume 







Monitor SVV Start inotrope
CI < target† 
reached?
Fluid bolus  
(250 mL) 
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will be included who are undergoing elective major gastro-
intestinal surgery. In this study, a cardiac-output guided 
hemodynamic maximization strategy with infusion of 
low-dose inotropes is compared to standard care (www.
optimiseii.org). A third study on the effect of early goal-
directed therapy on complications, quality of life and 
healthcare costs after high-risk abdominal surgery has 




One of the most important future directions of perioperative 
fluid management is the development of closed-loop fluid 
administration systems. Closed-loop fluid management 
makes use of dynamic hemodynamic variables, which aid in 
the assessment of fluid responsiveness. Minimally or non-
invasive hemodynamic monitors can be used to assess fluid 
responsiveness and the closed-loop systems then delivers 
a fluid bolus if the patient is considered fluid responsive. 
The hemodynamic effect of this fluid bolus is determined 
and this information is used in the decision to give another 
fluid bolus (86). Several studies have been performed using 
this concept and a novel closed-loop system was first tested 
using a computer simulation of hemorrhage scenarios 
(87,88), followed by an animal study, after which the system 
was studied in patients (89). These studies showed that 
closed-loop systems were more precise and performed more 
consistently compared to anesthesiologists. The closed-loop 
system was tested in moderate and high-risk patients for 
compliance to a PGDT strategy. The closed-loop system 
was successful in keeping patients in a preload independent 
state (PPV <13%) and with a CI >2.5 L min-1 m-2 for at least 
85% of the time (90,91).
Personalized hemodynamic management
A general problem of current fluid management is that 
patients are treated according to a one-size-fits-all approach. 
However, there is a considerable amount of variability 
between individual patients and thus PGDT should be 
individualized with the use of hemodynamic monitoring 
in order to assess fluid responsiveness and optimize blood 
flow. Subsequently, PGDT should be personalized with 
personal targets adjusted to several biometric factors (84). 
Age, bodyweight and height are independently associated 
with CO (92) and stroke volume decreases with age (93,94). 
Hemodynamic management could be optimized when 
individual ‘normal’ baseline values are obtained for each 
patient preoperatively. 
Conclusions
There are currently no universal standards for volume 
management. Crystalloids belong to the first-line agents for 
fluid therapy (both maintenance and replacement). Colloids 
are indicated for the treatment of severe hypovolemia/
hypovolemic shock (e.g., due to major bleeding) and can 
be used safely for short terms in the perioperative period 
when the dose limitations are respected. It is very complex 
to determine the best strategy for fluid administration and 
current evidence remains inconclusive. Most important, 
fluids should be administered with the same caution that is 
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